Alaya.bio

Alaya.bio is a private, preclinical biotech founded in 2021, focusing on nanoparticle-based delivery systems for next-generation CAR-T therapies. The company is developing a polymeric nanoparticle platform intended to overcome key limitations in current cell therapies, such as high cost, complex manufacturing, and poor efficacy in solid tumors, by enabling efficient in vivo genetic reprogramming of immune cells. With operations in Paris and Cambridge, MA, and led by a seasoned duo of biotech executives, the company is advancing its platform through key asset acquisitions and a collaboration with a leading global cancer center.

Targeting polymeric nanoparticle platform for enhanced in vivo transduction of quiescent immune cells (T-cells, NK-cells) while preserving naive and memory phenotypes.

Competes in the emerging in vivo cell engineering space with companies like Sana Biotechnology, Umoja Biopharma, Interius BioTherapeutics, and Tidal Therapeutics (acquired by Sanofi). Must differentiate on transduction efficiency, cell phenotype preservation, and safety profile.